U.S. Pharma Stock News

In March 2026, American Tower Corporation announced that director Robert D. Hormats will not stand for re-election, raised its quarterly cash distribution to US$1.79 per share, and participated in Deutsche Bank’s 34th Annual Media, Internet & Telecom Conference. Investor attention has also been shaped by Bernstein’s initiation of coverage, which emphasized American Tower’s global tower portfolio and its CoreSite data center business as key pillars of the company’s business profile. With...

Autodesk recently outlined its past fiscal fourth quarter performance at the Morgan Stanley Technology, Media & Telecom Conference, highlighting strong results across billings, revenue, margins and free cash flow despite macroeconomic uncertainty. The company also detailed a restructuring plan that includes a 7% workforce reduction to redirect resources toward artificial intelligence, cloud capabilities and its Construction Cloud and Fusion platforms, aiming to sharpen its focus on long-term...

In recent days, JPMorgan Chase has moved to reduce its exposure to the private credit market by marking down software-linked loans held as collateral and tightening or restricting lending to private credit providers, while simultaneously issuing a series of new long-dated, callable fixed-income securities and redeeming certain outstanding notes. This combination of proactive risk management in a stressed private credit segment and active balance sheet reshaping via bond issuance and...

Plexus recently reported a strong quarter with revenues of US$1.07 billion, up 9.6% year on year and in line with analyst expectations, while also exceeding forecasts for earnings per share and issuing higher-than-expected revenue guidance for the next quarter. Management highlighted especially strong momentum in Healthcare/Life Sciences and Aerospace/Defense, underscoring how its investments in talent, technology, and advanced capabilities are reinforcing these higher-complexity,...

If you are wondering whether Woodward's current share price still reflects good value, you are not alone. A closer look at how it is priced can help you decide what it might mean for your portfolio. The stock recently closed at US$356.80, with returns of 14.8% year to date and 98.5% over the past year, even after 7 day and 30 day declines of 4.6% and 8.4% respectively. Recent coverage has focused on Woodward's position in the capital goods space and how investors are reacting to its role in...

A shareholder activist has filed a proposal for West Pharmaceutical Services to permanently separate the CEO and Board Chair roles. The filing coincides with the company’s announcement that CEO and Chair Eric M. Green will retire once a successor is appointed. Investors will vote on the proposal at the upcoming annual meeting, putting corporate governance and board independence in focus. For investors watching NYSE:WST, this governance push comes at a time when the stock has seen mixed...

Director Carol Schneeberger has recently sold shares in Peoples Bancorp. The transactions involved insider stock sales with no corresponding insider purchases reported in the same period. The trades come with Peoples Bancorp shares last closing at $31.6 on the NasdaqGS under ticker NasdaqGS:PEBO. For investors tracking insider activity at Peoples Bancorp, the recent share sale by Director Carol Schneeberger adds a fresh data point to the story around NasdaqGS:PEBO. The stock last closed at...

Curious whether HNI at around US$40.50 is offering you real value today, or if the easy money has already been made? The stock is down about 2.3% over the last week and 21.7% over the last month, yet it still shows a 64.4% return over three years and 16.9% over five years. This contrast can change how investors think about both risk and potential. Recent coverage of HNI has focused on its positioning in commercial services and how investors are reassessing the company in light of changing...

KORU Medical Systems (KRMD) has just posted its FY 2025 third quarter numbers, with revenue of about US$10.4 million and a basic EPS loss of roughly US$0.02, underscoring that the company is still in the red. The company has seen revenue move from about US$8.2 million in Q3 FY 2024 to US$10.4 million in Q3 FY 2025, while quarterly basic EPS has ranged between a loss of roughly US$0.03 and US$0.02 over that period. As a result, investors are likely to focus on how quickly margins can tighten...

If you are wondering whether Cummins is still reasonably priced after its recent run, you are not alone. This article will help you frame that question clearly. The stock closed at US$535.71, with a 0.7% decline over the last 7 days, a 10.6% decline over 30 days, a 2.6% gain year to date, a 69.6% return over 1 year and a 154.7% return over 3 years. This naturally raises questions about where value sits today. Recent coverage has focused on Cummins as a long established industrial name with...

If you are wondering whether XPeng's current share price lines up with its underlying value, you are not alone. This article is going to focus squarely on that question. XPeng shares last closed at US$19.97, with recent returns of 15.3% over 7 days and 10.3% over 30 days. Year to date the stock shows a 2.3% decline and a 15.8% decline over 1 year, compared with a very large gain over 3 years and a 46.7% decline over 5 years. These swings have kept XPeng on many investors' watchlists, even as...

Recent performance snapshot Zurn Elkay Water Solutions (ZWS) has drawn attention after a period of mixed share performance, with the stock showing negative moves over the past week, month, past 3 months, and year to date, alongside a positive 1 year total return. See our latest analysis for Zurn Elkay Water Solutions. At a share price of US$45.73, Zurn Elkay Water Solutions has seen short term momentum fade, with a 1 month share price return decline of 11.29%. However, its 1 year total...

If you are wondering whether Daqo New Energy is priced attractively today, the key question is how its current share price lines up with its underlying business value. The stock last closed at US$23.11, with returns of 4.3% over 7 days, a 10.5% decline over 30 days, a 22.1% decline year to date, and a 21.2% gain over 1 year that sits against much weaker 3 year and 5 year returns of 49.4% and 70.8% declines. Recent price moves have been shaped by ongoing sector wide discussion around solar...

Recent performance snapshot Mueller Water Products (MWA) has drawn fresh attention after a mixed stretch in its share price, with a recent 0.4% daily gain contrasting with a 0.7% decline over the past week and a 5.8% pullback over the past month. Even so, the stock shows an 11.0% return over the past 3 months and a 15.9% gain year to date, alongside a 2.9% total return over the past year. This has prompted a closer look at how these moves line up with the company’s fundamentals. See our...

If you are wondering whether BrightView Holdings is attractively priced or just a value trap, you are in the right place to unpack what the current share price really reflects. The stock last closed at US$11.81, with returns of 7.2% decline over 7 days, 15.5% decline over 30 days, a 6.3% decline year to date, a 10.9% decline over 1 year, a 102.6% gain over 3 years and a 30.4% decline over 5 years. Taken together, this gives you a mixed picture of how sentiment has shifted over different...

If you are wondering whether Trinity Capital's current share price reflects its true worth, you are not alone. This article is set up to help you look past the headline numbers and into what the valuation actually implies. The stock last closed at US$14.42, with returns of 7.9% over 1 year and much stronger gains over 3 and 5 years. However, the last 7 and 30 days show declines of 3.3% and 8.8% that may have shifted how investors see the balance between opportunity and risk. Recent coverage...

Haemonetics (NYSE:HAE) is expanding its product portfolio in the Hospital division with new technology and acquisitions. The company has fully transitioned from legacy PCS2 plasma collection devices to its NexSys PCS system with Persona Technology. Recent purchases of Attune Medica and OpSens add new capabilities in hospital and interventional cardiology settings. For you as an investor, this shift is about more than one product line. Haemonetics operates across blood management and...

If you are wondering whether Karman Holdings at around US$99.98 is still fairly priced or starting to look stretched, you are not alone. The stock has seen a 25.7% return over the past 30 days, 30.1% year to date, and 201.5% over the last year, with a small 0.6% decline in the most recent 7 days. Recent coverage has focused on Karman Holdings as an evergreen story for investors who want ongoing insight into the stock, with attention on how its share price has moved over different time frames...

Why Sonida Senior Living Is On Investors’ Radar Sonida Senior Living (SNDA) has drawn attention after recent share price swings, with a 1 day return of 4.34% contrasting with a 4.28% decline over the past week. This has prompted closer portfolio reviews. See our latest analysis for Sonida Senior Living. That sharp 1 day share price return of 4.34% comes after a softer 7 day share price return of 4.28%. Sonida Senior Living still has a 90 day share price return of 13.06% and a 1 year total...

If you are wondering whether ACADIA Pharmaceuticals at around US$20.61 is offering good value or just fresh risk, you are in the right place for a closer look at what that price might represent. The share price has seen a 7% decline over the last week, an 8.3% decline over the last month, but a 17.8% return over the last year. This can leave investors questioning whether recent weakness is a setback or a reset after earlier gains. Recent attention on ACADIA has centered on its product...

In early March 2026, Abercrombie & Fitch Co. reported past fourth-quarter and full-year 2025 results with record sales of US$1,669.8 million and US$5,266.29 million respectively, even as net income eased to US$172.13 million for the quarter and US$506.92 million for the year, alongside ongoing share repurchases and new store expansion plans. The company coupled this performance with 2026 guidance targeting low single-digit net sales growth, double-digit operating margins of about 12.0% to...

If you are wondering whether Pulse Biosciences at around US$21.57 offers good value or is running ahead of itself, you are not alone. The stock has seen mixed recent moves, with an 18.9% return over the last 7 days, a 14.6% decline over the past 30 days, a 61.1% return year to date and a 27.6% return over the past year, while the 3 year return is very large and the 5 year return sits at an 8.5% decline. These moves have come against a backdrop of ongoing attention on Pulse Biosciences and...

Eastman Chemical (NYSE:EMN) has rolled out a new 2026 self help plan focused on deeper cost reductions and operational efficiency. The plan also targets expanded capital returns, signaling an intention to keep shareholder payouts in focus alongside internal improvements. Management is positioning the initiative as a material shift in how the company runs its business and allocates cash over the next few years. Eastman Chemical is launching this plan at a time when the stock has faced mixed...

Matador Resources (MTDR) is back on investors’ radar after BMO Capital reaffirmed its positive view on the stock, citing core acreage quality, operational execution, production trends, and recent balance sheet moves. See our latest analysis for Matador Resources. The 1-month share price return of 17.77% and 90-day share price return of 29.11% suggest momentum has been building. The 5-year total shareholder return of 152.21% points to meaningful longer term value creation for investors who...